Koistinen, H.; Boyd, S.; Arola, J.; Jokelainen, K.; Koistinen, R.; Lempiäinen, A.; Hotakainen, K.; Stenman, U.-H.; Färkkilä, M.
Biliary hCGβ Is a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients. Livers 2021, 1, 322-329.
https://doi.org/10.3390/livers1040025
AMA Style
Koistinen H, Boyd S, Arola J, Jokelainen K, Koistinen R, Lempiäinen A, Hotakainen K, Stenman U-H, Färkkilä M.
Biliary hCGβ Is a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients. Livers. 2021; 1(4):322-329.
https://doi.org/10.3390/livers1040025
Chicago/Turabian Style
Koistinen, Hannu, Sonja Boyd, Johanna Arola, Kalle Jokelainen, Riitta Koistinen, Anna Lempiäinen, Kristina Hotakainen, Ulf-Håkan Stenman, and Martti Färkkilä.
2021. "Biliary hCGβ Is a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients" Livers 1, no. 4: 322-329.
https://doi.org/10.3390/livers1040025
APA Style
Koistinen, H., Boyd, S., Arola, J., Jokelainen, K., Koistinen, R., Lempiäinen, A., Hotakainen, K., Stenman, U.-H., & Färkkilä, M.
(2021). Biliary hCGβ Is a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients. Livers, 1(4), 322-329.
https://doi.org/10.3390/livers1040025
